Biofrontera(NASDAQ) BFRIW

Biofrontera Inc. is a biopharmaceutical firm specializing in the commercialization of pharmaceutical solutions for skin-related ailments across the United States. The company offers innovative products aimed at treating conditions such as actinic keratosis and impetigo.

Products and Services

• Ameluz, a prescription drug for photodynamic therapy
• BF-RhodoLED lamp series for effective treatment
• Xepi, a topical treatment for impetigo

Growth Outlook

• Recent quarterly revenue increased to $12 million in Q2 2026
• Strong gross profit margin of 80% in the latest quarter
• Expansion plans targeting broader market reach in dermatology

Financial Highlights

• Net income of -$604,000 reported in Q2 2026
• Cash and cash equivalents at $4.7 million as of June 30, 2026
• Operating expenses totaled $10.1 million in the latest quarter

Biofrontera Inc. has established itself as a key player in the dermatological pharmaceutical market, focusing on innovative treatments that address significant skin conditions. The company's flagship product, Ameluz, is complemented by the BF-RhodoLED lamp series, enhancing treatment efficacy. Recent financial performance indicates a notable increase in revenue, reflecting growing market demand. Despite reporting a net loss, the company maintains a robust gross profit margin, suggesting effective cost management and potential for future profitability. With strategic growth initiatives underway, Biofrontera Inc. is positioned to expand its footprint in the healthcare sector, making it an intriguing option for investors interested in the biopharmaceutical industry.